Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC as maintenance therapy in moderately to severely active Crohn's disease
jRCT2031200117Phase 3Completed
- Sponsor
- Celltrion Healthcare
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing CT-P13 SC with Placebo SC (2 arms). Primary endpoint: Clinical remission at week 54. Started Sep 2020; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031200117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200117.